Oral Type I Collagen for Relieving Scleroderma

Status Completed

Clinical Trial Summary

Diffuse systemic sclerosis (SSc), or scleroderma, is a connective tissue disease causing damage to skin and other organs. The purpose of this study is to determine if taking oral bovine type I collagen (CI) will improve the condition of SSc patients.

Clinical Trial Description

SSc is a chronic connective tissue disease that is caused by excess collagen deposits that damage the skin and other organs. This study will determine if a daily oral dose of bovine CI will improve the condition of patients with SSc.

Patients will be randomly assigned to one of two groups. The first group will receive 500 mcg bovine CI daily for 15 months; the second group will receive placebo. Study visits will be conducted at Months 4, 8, 12, and 15. Patients will undergo physical examination and blood tests at each visit. Patients will also be evaluated for modified Rodnan skin score (MRSS) and will be given health assessment questionnaires. A chest x-ray will be conducted at study entry and pulmonary function tests will be conducted at study entry and Month 12. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00005675
Study type	Interventional
Source	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Contact
Status	Completed
Phase	Phase 2
Start date	April 2000

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02798055` - Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
Completed	`NCT01959815` - Novel Screening Strategies for Scleroderma PAH
Completed	`NCT03274076` - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Phase 1/Phase 2
Completed	`NCT02915835` - Riociguat in Scleroderma Associated Digital Ulcers	Phase 2
Active, not recruiting	`NCT01895244` - Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis	Phase 2
Completed	`NCT00883129` - Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)	Phase 2
Completed	`NCT00930683` - A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma	Phase 1
Completed	`NCT00074568` - Scleroderma Registry
Recruiting	`NCT04797286` - Sildenafil for Early Pulmonary Vascular Disease in Scleroderma	Phase 2
Completed	`NCT03222492` - Brentuximab Vedotin for Systemic Sclerosis	Phase 1/Phase 2
Completed	`NCT03207997` - MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients	N/A
Recruiting	`NCT04464434` - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis	Phase 4
Recruiting	`NCT04246528` - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF)	N/A
Completed	`NCT05080738` - Upper Extremity Home Exercises in Patients With Scleroderma	N/A
Recruiting	`NCT03726398` - CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH	Phase 2/Phase 3
Recruiting	`NCT05085444` - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma	Early Phase 1
Completed	`NCT02062125` - Calcinosis in a Single-Center Scleroderma Population
Completed	`NCT04588714` - Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention	N/A
Recruiting	`NCT05635266` - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT02835196` - Optical Elastography of Systemic Sclerosis Skin